Decision making on the route and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analyses considering the effectiveness and harms of antibiotic treatment.

Running title: Antibiotic treatment decision making for acute cellulitis

Elizabeth LA Cross[a,b], Harriet Jordan[b], Rebecca Godfrey[b], Igho J Onakpoya[c], Annalie Shears[b], Katy Fidler[a,b], Timothy EA Peto[c-e], A Sarah Walker[c-e], Martin J Llewelyn[a,b]

[a.] Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, UK
[b.] Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
[c.] Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford UK
[d.] Oxford University Hospitals NHS Foundation Trust, Oxford UK
[e.] NIHR Biomedical Centre, Oxford, UK (Prof T EA Peto DPhil, Prof A S Walker PhD)

Corresponding author: Prof Martin J Llewelyn, Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, East Sussex, BN1 9PS, UK, +44 (0)1273 876671, **m.j.llewelyn@bsms.ac.uk**

Abstract

Objectives

Compared with guideline recommendations, antibiotic overuse is common in treating cellulitis. We conducted a systematic review and meta-analyses on antibiotic route and duration of treatment for cellulitis in adults and children.

Methods

We searched MEDLINE, EMBASE and trial registries from inception to Dec 11, 2019 for interventional and observational studies of antibiotic treatment for cellulitis. Exclusions included case series/reports, pre-septal/orbital cellulitis and non-English language articles. Random-effects meta-analyses were used to produce summary relative risk (RR) estimates for our primary outcome of clinical response.

PROSPERO:CRD42018100602.

Results

We included 47/8423 articles, incorporating data from eleven trials (1855 patients) in two meta-analyses. The overall risk of bias was moderate. Only two trials compared the same antibiotic agent in each group. We found no evidence of difference in clinical response rates for antibiotic route or duration (RR(oral:IV)=1·12, 95%CI 0·98-1·27, I^2=32% and RR(shorter:longer)=0·99, 95%CI 0·96-1·03, I^2 = 0%, respectively). Findings were consistent in observational studies. Follow-up data beyond 30 days were sparse.

Conclusions

The evidence base for antibiotic treatment decisions in cellulitis is flawed by biased comparisons, short follow-up and lack of data around harms of antibiotic overuse. Future research should focus on developing patient-tailored antibiotic prescribing for cellulitis to reduce unnecessary antibiotic use.

Keywords

Cellulitis; Erysipelas; Soft tissue Infections; Anti-Bacterial Agents; Duration of Therapy; Administration, Intravenous; Administration, Oral

Introduction

Cellulitis is the commonest form of acute skin and soft tissue infection (SSTI), characterised by spreading redness, oedema and induration, usually affecting the lower limb.[1] The term encompasses erysipelas, which is no longer considered a distinct entity, and does not apply to inflammation associated with collections of pus (e.g. around skin abscesses) for which the primary treatment is drainage rather than antibiotic therapy.[1] Cellulitis is predominantly a community onset infection, typically affecting older adults.[2] Recent data from the United States (US) show that SSTI incidence in older adults almost doubled between 2000 and 2012 (from 67-130 per 10,000 persons) with the associated healthcare costs tripling to 15 billion USD.[3] From 2000-2018, the proportion of emergency admissions due to cellulitis in England increased by more than one third (0·9 to 1·3%).[4] Over 90% of patients with cellulitis are treated in ambulatory care.[5]

The main causative organisms of cellulitis are beta-haemolytic streptococci, especially *Streptococcus pyogenes,* and *Staphylococcus aureus*[6,7] while other bacterial species are linked to specific patient risk factors.[2] Guidelines recommend antibiotic agents for cellulitis based on susceptibility of key pathogens, but clinicians then have three decisions as they seek to avoid antibiotic overuse whilst ensuring good treatment outcomes for their patients;[8] whether intravenous (IV) treatment is indicated; when to switch from IV to oral; and what total duration of treatment is needed. Decisions about whether to initiate IV or oral treatment should be based on severity of illness[9] but 30-50% of patients eligible for oral therapy receive IV antibiotics and then many remain on them for longer than necessary.[10-12] International recommendations for treatment duration in cellulitis are inconsistent and range from 5[1,13] to 10-14 days,[14,15] but in practice durations commonly exceed two weeks.[11,12] A recent review addressing antibiotic treatment of cellulitis in adults identified four randomised controlled trials (RCTs) comparing oral versus IV therapy, none focusing on IV-to-oral switch and five trials addressing treatment duration.[16]

We aimed to systematically review the literature on decisions about initial treatment with IV versus oral therapy, timing of IV-to-oral switch and duration of therapy in

cellulitis, considering both effectiveness and harms of antibiotic treatment. Where randomised trials exist, we conducted meta-analysis, and have also summarised relevant data from non-experimental studies. We considered studies involving both adults and children.

Methods

Search strategy and selection criteria

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (checklist in appendix p1).[17] We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the ISRCTN registry, the U.S National Institute of Health ongoing trials register, the Australian and New Zealand Clinical Trials Registry and the World Health Organization International Clinical Trials Registry from database inception to Dec 11, 2019. Search terms covered the population (cellulitis/erysipelas/skin infection) and intervention (antibiotics/duration/route) (appendix p4). Only articles in the English language were considered. The protocol is available at www.crd.york.ac.uk/PROSPERO, CRD42018100602.

Studies were eligible if they investigated humans (adults or children) treated with oral or IV antibiotics for cellulitis. Those including only patients with pre-septal or orbital cellulitis were excluded. Studies assessing SSTIs in general were excluded, unless data for the cellulitis subpopulation could be separated. Studies that investigated antibiotic prophylaxis or solely topical antibiotic therapy were excluded. Both interventional and observational studies were included but case series and case reports were not. RCTs were restricted to comparisons of shorter versus longer antibiotic courses or oral versus IV antibiotics as initial treatment. Observational studies were required, as a minimum, to report the average duration of antibiotic therapy used and one of the outcome measures below.

Data extraction and quality assessment

Titles and abstracts were screened by one author (ELAC) with a random 20% screened by another (HJ), calculating inter-observer agreement using Cohen's kappa.[18] All potentially eligible full text articles were independently reviewed by two of four authors (ELAC, HJ, RG, AS). Any disagreement was resolved by consensus, referring to a third author if necessary. Double data extraction was performed independently by the same authors on published reports using standardised, pre-piloted forms (appendix p3). Data were extracted on study methods, population and participant characteristics (setting, demographics, comorbidities, illness severity),

interventions (antibiotic agent, route, duration and co-interventions), individual patient-level outcomes (below), key conclusions drawn by authors, and study funding.

RCTs were assessed for risk of bias using the Cochrane Risk of Bias Tool.[19] Non-randomised studies were assessed using an abridged Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist, focusing on items 4-12 to assess methodological quality.[20] Two authors (ELAC, IJO) independently assessed the risk of bias and quality of included studies; disagreements were resolved via consensus. The quality of the evidence for studies included in the meta-analyses was assessed using the Grading of Recommendation, Assessment, Development and Evaluation criteria.[21]

Outcomes

Our primary outcome measure was clinical response, defined as improvement or lack of progression of signs and symptoms, assessed as a measure of treatment effect at a timepoint specified by study authors. Additional secondary outcome measures of effectiveness included clinical/therapeutic failure, recurrence, microbiological cure/bacteriological response, mortality, biochemical response and patient-focused outcomes. We also considered balancing outcomes e.g. length of stay (LOS), adverse events and development of antibiotic resistance.

Data analysis

Where there was evidence of substantial clinical heterogeneity, narrative synthesis was performed. Where pooling of results was feasible, meta-analysis was performed using the random-effects model. One author (IJO) entered the data onto RevMan,[22] which was independently cross-checked by a second author (ELAC). Statistical heterogeneity of included studies was assessed using the Chi-square test (threshold $P<0·1$) and the I^2 statistic. I^2 values <25% were considered to represent low heterogeneity, values 25-75% moderate heterogeneity, and values >75% high heterogeneity. Results from meta-analyses are presented as RR, with 95% confidence intervals (95% CI) and two-sided P values (threshold $P<0·05$). An assessment of publication bias was not performed due to the small number of studies included in each meta-analysis (<10).

Results

The initial search yielded 8423 articles. Title and abstract screening identified 604 articles for full-text screening of which 557 were excluded. Inter-observer agreement was moderate at title and abstract screening (Kappa=0·66, 95%CI 0·59-0·73). Among the 47 included articles, one described two RCTs yielding a total of 48 studies (figure 1): 16 RCTs (including one quasi-RCT),[23-37] two non-randomised interventional studies[38,39] and 30 observational studies.[40-68] Eleven RCTs were included in two separate meta-analyses.

Figure 2 summarises the risk of bias across the RCTs. In eight RCTs, the method of sequence generation or allocation concealment was not adequately reported. Nine RCTs were either open-label or failed to report that they were blinded. The overall risk of bias across the RCTs was considered moderate. For non-randomised studies; five were considered high quality, 19 moderate quality and eight low quality. The risk of bias and quality assessment of each individual study are in appendix tables 1-5.

Only eight studies measured clinical outcomes beyond 30 days. In the remainder, outcomes were assessed within 30 days (12/48), within two weeks (12/48), within the first 48-72 hours (4/48); 12 studies did not clearly report the timing of outcome assessment.

Evidence for selecting oral versus IV antibiotics

Five RCTs compared oral versus IV route of initial treatment for adults with cellulitis (table 1). All studies were conducted in high-income countries. Four of the five studies included patients with cellulitis who were admitted to hospital. All trials included non-necrotising cellulitis, but various descriptions were used to indicate the severity of disease. One study specifically stated included patients must have a severity of cellulitis that warranted treatment with IV antibiotics,[23] another study stated that included patients had to have 'severe local findings'.[27] All studies required patients to have a fever of ≥38°C (with one trial also requiring tachycardia of >90 beats/min),[23] but all trials excluded patients with features of severe sepsis. Two studies compared antibiotics of the same class in both oral and IV groups. The remainder compared oral agents likely to have good efficacy in cellulitis (clindamycin, roxithromycin and pristinamycin) with IV penicillin.

In terms of treatment effectiveness, three of the five RCTs assessed clinical response rates and were included in the meta-analysis (N=397) (figure 3). There was no evidence of difference in clinical response rates between oral versus IV groups (RR(oral:IV)=1·12, 95%CI 0·98-1·27, I^2=32%). The two remaining studies were not included in the meta-analysis since they reported different outcome measures. Aboltins found no evidence of a difference in mean days until no advancement of the area of cellulitis (mean difference -0·49, 95%CI -1·02 to +0·04) and in treatment failure rates between oral and IV groups (4% versus 22%, P=0.10).[23] Jorup-Rönström assessed efficacy by the time to body temperature reduction to ≤37·5°C and found no evidence of difference between groups.[27] Two RCTs reported similar rates of relapse or recurrence of 16% versus 14% at 4 weeks[26] and 11% versus 16% at 6 months[27] for oral versus IV treatment respectively. The single RCT that reported patients' pain scores and satisfaction with treatment found no evidence of differences between groups.[23]

In terms of treatment-associated harms, all studies reported data on adverse events with only one finding evidence of differences between treatment groups; namely a higher rate of adverse events in the oral (pristinamycin) versus IV (penicillin) group, 28% versus 17% (P=0·03).[25] However, there was no evidence of difference in the proportions of adverse events necessitating discontinuation of study medication between the two groups (11% versus 17%, respectively, P=0·17). Two studies reported *C. difficile*-associated diarrhoea as an outcome, but no cases occurred.[26,27] Three studies compared average hospital LOS, which ranged between 3 and 11 days, and found no evidence of difference between randomised groups.[25-27] No trials reported on the development of antibiotic resistance.

Evidence for timing of intravenous-to-oral switch

A single RCT compared efficacy of early (24h) versus later (≥72h) switch to oral antibiotics in uncomplicated cellulitis requiring IV antibiotics (table 2).[28] Resolution of cellulitis was achieved in 79% and 84% of patients in the of shorter (24h and longer (>72 hour) treatment groups respectively but the study sample size was too small to demonstrate non-inferiority. Decreases in patient-reported pain scores were similar between groups. The only treatment-associated harm reported was from a patient in the shorter group who experienced headaches and non-*C. difficile* diarrhoea.

We did not identify any non-randomised comparative studies of different IV to oral switch timing. However, six observational studies reported average durations of IV antibiotics for both adult and paediatric patients with complicated cellulitis;[40-45] these were consistently around 1-3 days prior to oral-switch but often ranged up to 14 days (table 2, appendix table 6). None of the studies reported relationships between timing of IV-to-oral switch and adverse events, frequency of *C. difficile* infection or antibiotic resistance.

Evidence for overall duration of therapy

Data on clinical outcomes among patients with cellulitis randomised to either shorter versus longer antibiotic durations were available for 1508 patients in 10 RCTs (table 3). Seven studies recruited only adults, only one outside Europe and North America. Most trials reported outcomes for cellulitis as a subset of patients with SSTIs, two of these included patients with complicated SSTIs[32,33] but most of the other studies lacked detail regarding the severity of cellulitis. As part of the inclusion criteria, the minimum total lesion surface area was 75cm^2 accompanied by at least one regional or systemic sign of infection (10-30% of patients had fever at baseline). Four used antibiotics of the same class in both groups (macrolides and oxazolidinones) and four compared different classes of antibiotics in each group. In each the choice of short-course agent was based on anticipated longer duration of action. Five used azithromycin and three used tedizolid. The difference between shorter and longer treatment groups ranged from two to seven days.

Two trials specifically studied patients with cellulitis and used the same antibiotic agent (flucloxacillin) in both shorter and longer duration groups. One included mostly outpatients with uncomplicated cellulitis who received oral therapy, the mean age was 40 years, 16% had diabetes mellitus, 10% had a fever and the average cellulitis severity score was 6.5.[31] The other trial included hospitalised patients requiring IV therapy who were on average 20 years older (mean age 60 years), 24% had diabetes, 47% had fever and the average severity score was 8.5.[35]

In terms of treatment effectiveness, the eight RCTs that studied mainly adults were included in the meta-analysis (N=1458, figure 4). Clinical response rates varied from 49-100% between trials and there was no evidence of difference in response rates between shorter versus the longer antibiotic groups (RR(shorter:longer)=0·99, 95%CI

0·96-1·03, I^2 = 0%). Three RCTs examined bacteriological response to antibiotic therapy, defined as the disappearance of a pathogen that was identified from culture at baseline after treatment with antibiotic therapy.[29,36] One found higher responses in the shorter (macrolide) versus the longer (penicillin) group (33% versus 15%, P=0·04).[29] Another RCT comparing two macrolides found a trend towards a higher response rate in the shorter (89%) versus the longer (78%) group.[29] In the third RCT, 100% of patients achieved bacteriological response in both groups.[36]

The two trials to describe patient-reported outcomes found no evidence of differences in pain and swelling scores between the shorter and longer groups.[31,35]This was the same for the physician reported clinical scores.

The only RCT to measure clinical outcomes beyond 30 days was the Duration of ANtibiotic Therapy for CEllulitis "DANCE" trial which randomised 151 hospitalised patients to receive 6 versus 12 days of flucloxacillin and followed patients to day 90.[35] Although there was no evidence of differences between groups at day 28, more recurrences occurred in the shorter treatment group compared to the longer group between day 28 and day 90 (24% versus 6%, P=0·045).

Four non-randomised comparative studies reported effectiveness outcomes for patients with cellulitis receiving shorter versus longer durations of antibiotic therapy (table 4, appendix table 7). Two were non-randomised interventional studies and achieved modest reductions in antibiotic duration after implementing new management guidelines/ protocols for cellulitis.[38,39] Three studies found no evidence of a reduction in effectiveness with shorter treatment durations.[38,39,46] Conversely, one study that focused on children reported a significantly higher odds ratio (OR) of treatment failure for patients treated with short-course IV therapy versus inpatient IV therapy (OR=7·2, 95%CI 1·6-33·1), and outpatient oral antibiotics (OR=3·2, 95%CI 1·3-8·3).[47] The duration of short-course IV therapy was not clearly defined but 73% of patients in this group received ≤2 doses of IV antibiotics.

We identified a further twenty-two studies which reported the average length of antibiotic treatment for patients with cellulitis and at least one relevant outcome measure (appendix tables 8 and 9). These studies included populations that were generally older, with a higher illness severity and more comorbidities than those recruited to the RCTs. For instance, studies of inpatients had a mean age range from

48 to 70 years and 20-35% had diabetes. Eleven studies included inpatients and reported an average length of antibiotic treatment of 5-17 days.[40,46,48,49,52-54,57,58] Clinical response rates were all above 85%, failure rates ranged from 5-12% and recurrence rates from 0-17%. Eleven studies, including those treated as outpatients/OPAT, reported an average length of IV therapy of 2-7 days and an average overall treatment duration of 6-10 days.[59-69] Clinical response rates ranged from 85-97%, failure rates from 5-22% and recurrence rates from 0-6%.

Across these studies, patient factors emerged as the key determinants of clinical response, while no evidence of associations between duration of therapy and outcome was reported. In studies comparing patients with better versus worse outcomes, groups with poorer outcomes had higher proportions of patients with prior cellulitis, sepsis at presentation and comorbidities (including diabetes, immunosuppression, obesity and venous insufficiency).[40,48,50,55,60,62]

With regards to treatment-associated harms, data on adverse events were not reported separately for cellulitis patients within SSTI trials, but overall, three trials found a higher incidence of gastrointestinal side-effects among patients receiving longer treatment (linezolid and erythromycin) versus shorter treatment (tedizolid and azithromycin).[29,32,33] One trial found no difference in gastrointestinal side effects between groups.[34] Only two of these reported that no cases of diarrhoea were associated with *C. difficile*.[33,34] One RCT found a higher proportion of side-effects in the shorter (azithromycin) versus the longer (cloxacillin) group, but severe events requiring study withdrawal were more frequent in the longer group.[29] No trials reported on the development of antibiotic resistance.

Evidence from paediatric studies

There were 7 studies that focused on paediatric populations.[36,37,44,45,47,58,68] Overall, the paediatric studies included a lower proportion of patients with lower limb cellulitis (~40%) compared to adult studies. Only three of the studies stated the severity of infection, which was reported as uncomplicated moderate/severe cellulitis.[44,45,68] None of the paediatric studies compared oral to IV antibiotic therapy.

Two of the paediatric observational studies reported average IV-to-oral switch durations between 1.8-2.5 days with a maximum duration of 2.6 days,[44,45] compared to adult studies where the maximal average duration was 15 days. The average total

duration of antibiotic therapy reported in paediatric studies was 8-11 days with treatment failure rates of 0-5%, compared to an average duration of 5-17 days in adults with failure rates from 5-22%.

Two RCTs compared shorter versus longer duration of antibiotic therapy in children.[36,37] The trials were conducted in low- and middle-income countries as opposed to adult studies where the majority were conducted in high-income countries. They both compared different classes of antibiotics in each group. Similar to the adult studies, the choice of short-course agent was based on anticipated longer duration of action. However, the short-course therapy duration was shorter at 3 days versus 5-6 days in adult studies. The clinical response rates of 81-100% were comparable to response rates seen in adult populations.

Discussion

We have undertaken a comprehensive systematic review of all available published evidence supporting decisions about the initial route of administration and duration of antibiotic therapy for adults and children with cellulitis. Our findings expand on those of a recent review which concluded there is a lack of evidence to support use of IV over oral antibiotics and treatment for longer than 5 days in cellulitis.[16] The findings of a recent trial by Cranendonk *et al.* highlight that more patients can achieve good long-term outcomes with more prolonged therapy.[35] We have also considered data from non-randomised studies and paediatric studies but crucially we have considered potential harms of antibiotic therapy, highly relevant to clinicians aiming to optimise antibiotic treatment in cellulitis. We have identified 48 relevant studies, many of low or very low quality, whose interpretation is further hampered by the heterogeneity of outcome measures, highlighted previously as a major limitation in this area.[70] Further general limitations of the evidence are vagueness of the case definition of cellulitis, a potential misdiagnosis rate of ~30%,[71] and the fact that participants had often received antibiotics prior to enrolment, minimising differences in treatment effectiveness between groups.[72,73]

Currently, the available evidence suggests that for adults with cellulitis clinical response rates are similar for initial oral and IV antibiotic treatment. While this is the consistent finding of five trials, all are of low or very low quality. None provide data relevant to patients with complicated disease or markers of sepsis. Another key limitation is that studies often compare agents of different classes. Only two trials compare antibiotic route using drugs of the same class and two trials compare oral to IV agents with different anti-staphylococcal activity. Therefore, their findings can only be applied in clinical practice with great caution and may be affected in settings with differing epidemiology of *S. pyogenes* and *S. aureus*. Nevertheless, overall, these trials indicate that if initial oral therapy is less effective than initial IV the difference is likely to be <2%. However, they do not provide evidence that oral treatment is superior to IV treatment through any balancing treatment-related harm outcomes such as side-effects, *C. difficile* infection or antibiotic resistance.

The question of timing of IV-to-oral switch has been addressed in only a single trial which was too small to demonstrate non-inferiority and again included only a subset of patients with uncomplicated cellulitis.[28]

Although we identified ten randomised trials providing evidence on duration of therapy, a major limitation of this evidence base is that eight of the trials use short-course treatment with agents anticipated to have longer durations of action compared to the longer-course agent used. For instance, azithromycin is used as the short-course agent in half of the trials on duration but is known to have a longer serum half-life than the other antibiotics. The comparisons are therefore severely flawed and their findings of limited relevance to clinical decision making. Current guidelines recommending 5 days treatment of cellulitis[1,13] are based on a single trial that used levofloxacin, which is not a recommended first-line treatment.[31] Overall these trials indicate that for early clinical cure, if short-duration treatment of cellulitis is associated with any loss of effectiveness, this is likely to be small (<4%). The one study which found shorter treatment to be associated with reduced early clinical cure reported 7.2% failure for the cohort overall.[47] This illustrates an important point. Across all the studies reviewed, the overwhelming majority of patients achieved clinical success irrespective of the initial route or duration of therapy. Patients with comorbidities, such as diabetes or who have experienced previous cellulitis, may be at increased risk of treatment failure but the value of IV or prolonged treatment in these patients remains unproven.

There is a particular lack of data around outcomes beyond 30 days to allow an assessment of the impact on recurrence. A particularly striking finding of the DANCE trial was increased recurrence up to 90 days among patients receiving shorter initial therapy.[35] These results suggest that recurrence may be due in part to recrudescence of infection rather than reinfection and that long-term recurrence may be tractable to optimised initial therapy.[35]

The paediatric studies we have identified illustrate important differences compared with adult disease. In particular that fewer patients have lower limb disease and that treatment durations and recurrence rates are lower. That two paediatric trials were conducted in low- and middle-income countries reflects the greater incidence of paediatric streptococcal skin infection in hotter climates and overcrowded communities. Nevertheless, findings of the paediatric studies that short duration oral therapy is highly effective in cellulitis are entirely consistent with those of studies in adults.

Our study has major strengths. We conducted an extensive literature search across all major relevant databases including observational studies. This allowed us to

include evidence which informs clinical practice but is not captured in existing overviews of this literature, and to include patients who would not ordinarily have been enrolled into trials because of significant comorbidities and illness severity. By addressing both effectiveness and treatment-related harms our analysis highlights a major gap in the evidence in this field. Unless antibiotic-reduction strategies are superior in ways which are meaningful to individual patients (e.g. fewer adverse effects, less antibiotic resistant infections) even marginal concern about loss of effectiveness will limit translation of findings into practice.[74]

Our study has several limitations. We have only searched for articles in English and did not search unpublished/grey literature. It is possible but unlikely that we have missed evidence which would have changed our conclusions. We have been unable to assess the impact of publication bias due to the small number of studies included in each meta-analysis (<10). The small number of studies available may make the random-effects meta-analysis approach we have used unreliable, but this remains the most appropriate method.[75] There is a risk that some relevant studies could have been incorrectly excluded as only 20% of identified papers underwent dual title and abstract screening. However, there was substantial agreement between reviewers for dual screened studies (1465/1550, 95%) and it is unlikely we have missed evidence which would have changed our conclusions. We chose to use an abridged STROBE statement to assess the quality of observational studies as there is no consensus on the optimal tool to use. While STROBE was not designed for this purpose, it provides a useful recommendation of the essential information required to assess the conduct of observational studies.[76]

In summary although the efficacy of oral antibiotics in cellulitis is long established,[77,78] there is a striking lack of evidence that initial IV therapy or treatment beyond 5-7 days are more effective than initial oral or short course treatment. However, this does not preclude initial IV treatment and prolonged therapy being more effective in some scenarios. This is particularly the case for commonly used agents such as beta-lactams, since most studies have used less widely used agents, and for patients with complicated disease, who have been excluded from most studies. Indeed, the DANCE trial highlights that although most patients achieve lasting cure with short durations of therapy, a small number of patients do require longer treatment.[35] The challenge for future research is personalising treatment decisions about duration of therapy. The

evidence is further limited by inappropriate comparisons, heterogenous outcomes, and lack of long-term follow up. In particular, the lack of data around the harms of IV and prolonged antibiotic treatment hampers clinical decision making. It is likely this contributes to clinicians choosing to exceed guideline recommendations. Observational data suggest that prior cellulitis, illness severity and the presence of certain comorbidities are likely to be important in influencing clinical outcomes. Future research should focus on developing patient-tailored recommendations for antibiotic treatment in cellulitis and establishing the individual patient benefits of reduced antibiotic exposure.

Contributors

ELAC, IJO, KF and MJL designed the study. EC, RG, HJ, IJO and AS were responsible for collecting and analysing the data, under the guidance of KF, TEAP, SAW and MJL. ELAC and MJL were responsible for drafting the manuscript, with support and input from the other co-authors. All authors critically reviewed and approved the final manuscript.

References

1.   Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin Infect Dis* 2014; **59**(2): 147-59. 10.1093/cid/ciu296

2.   Raff AB, Kroshinsky D. Cellulitis: A review. *JAMA* 2016; **316**(3): 325-37. 10.1001/jama.2016.8825

3.   Tun K, Shurko JF, Ryan L, et al. Age-based health and economic burden of skin and soft tissue infections in the United States, 2000 and 2012. *PLoS One* 2018; **13**(11): e0206893. 10.1371/journal.pone.0206893

4.   Health & Social Care Information Centre. Hospital Episode Statistics. Admitted Patient Care.; 2018.

5.   Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010. *BMC Infect Dis* 2015; **15**: 362. 10.1186/s12879-015-1071-0

6.   Bruun T, Oppegaard O, Kittang BR, et al. Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study. *Open Forum Infect Dis* 2016; **3**(1): ofv181. 10.1093/ofid/ofv181

7.   Hook EW, 3rd, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. *Arch Intern Med* 1986; **146**(2): 295-7.

8.   McGowan JE, Jr., Gerding DN. Does antibiotic restriction prevent resistance? *New Horiz* 1996; **4**(3): 370-6.

9.   Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. *J Antimicrob Chemother* 2003; **52 Suppl 1**: i3-17. 10.1093/jac/dkg466

10.   Quirke M, Saunders J, O'Sullivan R, et al. The management of cellulitis in emergency departments: Antibiotic-prescribing practices and adherence to practice guidelines in Ireland. *Eur J Emerg Med* 2016; **23**(3): 173-8. 10.1097/MEJ.0000000000000245.

11.   Nathwani D, Eckmann C, Lawson W, et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. *Clin Microbiol and Infec* 2014; **20**(10): 993-1000. 10.1111/1469-0691.12632.

12.   Walsh TL, Chan L, Konopka CI, et al. Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients. *BMC Infect Dis* 2016; **16**(1): 721. 10.1186/s12879-016-2067-0

13.   Kwak YG, Choi SH, Kim T, et al. Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection. *Infect Chemother* 2017; **49**(4): 301-25. 10.3947/ic.2017.49.4.301

14.   Clinical Resource Efficiency Support Team. Guidelines on the management of cellulitis in adults. Belfast: CREST; 2005.

15.   National Institute for Health and Care Excellence and Public Health England. Summary of antimicrobial prescribing guidance - managing common infections. London: PHE; 2019.

16.   Brindle R, Williams OM, Barton E, et al. Assessment of Antibiotic Treatment of Cellulitis and Erysipelas: A Systematic Review and Meta-analysis. *JAMA Dermatol* 2019. 10.1001/jamadermatol.2019.0884

17.   Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700. 10.1136/bmj.b2700

18.   Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam Med* 2005; **37**(5): 360-3.

19.   Higgins JPT, Altman DG, Sterne JACe. Chapter 8: Assessing risk of bias in included studies. In: Higgins, J.P.T., Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. London: The Cochrane Collaboration.; 2011.

20.   von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; **61**(4): 344-9. 10.1016/j.jclinepi.2007.11.008

21.   Schünemann 2013; Schünemann H BJ, Guyatt G, Oxman A (editors). The GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated in 2013.

22.   Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.

23.   Aboltins CA, Hutchinson AF, Sinnappu RN, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. *J Antimicrob Chemother* 2015; **70**(2): 581-6. 10.1093/jac/dku397

24.   Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. *Br J Dermatol* 1992; **127**(2): 155-9. 10.1111/j.1365-2133.1992.tb08048.x

25.   Bernard P, Chosidow O, Vaillant L, et al. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. *BMJ* 2002; **325**(7369): 864. 10.1136/bmj.325.7369.864

26.   Thomas MG. Oral Clindamycin Compared With Sequential Intravenous and Oral Flucloxacillin in the Treatment of Cellulitis in Adults. *Infect Dis Clin Prac* 2014. 10.1097/ipc.0000000000000146

27.   Jorup-Ronstrom C, Britton S, Gavlevik A, et al. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. *Infection* 1984; **12**(6): 390-4. 10.1007/bf01645222

28.   Clarke MC, Cheng AC, Pollard JG, et al. Lessons Learned From a Randomized Controlled Trial of Short-Course Intravenous Antibiotic Therapy for Erysipelas and Cellulitis of the Lower Limb (Switch Trial). *Open Forum Infect Dis* 2019; **6**(9): ofz335. 10.1093/ofid/ofz335

29.   Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. *J Int Med Res* 1991; **19**(6): 433-45. 10.1177/030006059101900602

30.   Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. *Eur J Clin Microbiol Infect Dis* 1991; **10**(10): 880-4. 10.1007/bf01975848

31.   Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. *Arch Intern Med* 2004; **164**(15): 1669-74. 10.1001/archinte.164.15.1669

32.   Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. *JAMA* 2013; **309**(6): 559-69. 10.1001/jama.2013.241

33.   Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* 2014; **14**(8): 696-705. 10.1016/S1473-3099(14)70737-6

34.   Lv X, Alder J, Li L, et al. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. *Antimicrob Agents Chemother* 2019; **63**(7): e02252-18. 10.1128/AAC.02252-18

35.   Cranendonk DR, Opmeer BC, van Agtmael MA, et al. Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomised, double-blind, placebo-controlled, non-inferiority trial. *CMI* 2019. 10.1016/j.cmi.2019.09.019

36.   Rodriguez-Solares A, Pérez-Gutiérrez F, Prosperi J, et al. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. *J Antimicrob Chemother*, 1993; **31**(Suppl E): 103-9. 10.1093/jac/31.suppl_e.103

37.   Montero L. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. *J Antimicrob Chemother* 1996; **37(Suppl C)**: 125-31. 10.1093/jac/37.suppl_c.125

38. Jenkins TC, Knepper BC, Sabel AL, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. *Arch Intern Med* 2011; **171**(12): 1072-9. 10.1001/archinternmed.2011.29

39. Seaton RA, Bell E, Gourlay Y, et al. Nurse-led management of uncomplicated cellulitis in the community: Evaluation of a protocol incorporating intravenous ceftriaxone. *J Antimicrob Chemother* 2005; **55**(5): 764-7. 10.1093/jac/dki092

40. Bogner JR, Kutaiman A, Esguerra-Alcalen M, et al. Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study. *Adv Ther* 2013; **30**(6): 630-43. 10.1007/s12325-013-0038-z

41. Lipsky BA, Moran GJ, Napolitano LM, et al. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. *BMC Infect Dis* 2012; **12**: 227. 10.1186/1471-2334-12-227.

42. Morpeth SC, Chambers ST, Gallagher K, et al. Lower limb cellulitis: features associated with length of hospital stay. *J Infect* 2006; **52**(1): 23-9. 10.1016/j.jinf.2005.02.017

43. McNamara DR, Tleyjeh IM, Berbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. *Arch Intern Med* 2007; **167**(7): 709-15. 10.1001/archinte.167.7.709

44. Gouin S, Chevalier I, Gauthier M, et al. Prospective evaluation of the management of moderate to severe cellulitis with parenteral antibiotics at a paediatric day treatment centre. *J Paediatr Child Health* 2008; **44**(4): 214-8. 10.1111/j.1440-1754.2007.01236.x

45. Ibrahim LF, Hopper SM, Connell TG, et al. Evaluating an admission avoidance pathway for children in the emergency department: Outpatient intravenous antibiotics for moderate/severe cellulitis. *Emerg Med J* 2017; **34**(12): 780-5. 10.1136/emermed-2017-206829.

46. Aly AA, Roberts NM, Seipol KS, et al. Case survey of management of cellulitis in a tertiary teaching hospital. *Med J Aust* 1996; **165**(10): 553-6.

47. Kam AJ, Leal J, Freedman SB. Pediatric cellulitis: Success of emergency department short-course intravenous antibiotics. *Pediatr Emerg Care* 2010; **26**(3): 171-6. 10.1097/PEC.0b013e3181d1de08.

48. Collazos J, de la Fuente B, Garcia A, et al. Cellulitis in adult patients: A large, multicenter, observational, prospective study of 606 episodes and analysis of the factors related to the response to treatment. *PLoS One* 2018; **13**(9): e0204036. 10.1371/journal.pone.0204036

49. LeFrock JL, Johnson ES, Smith LG, et al. Noncomparative trial of ticarcillin plus clavulanic acid in skin and soft tissue infections. *Am J Med* 1985; **79**(5 B): 122-5. 10.1016/0002-9343(85)90143-3

50. Carratala J, Roson B, Fernandez-Sabe N, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. *Eur J Clin Microbiol Infect Dis* 2003; **22**(3): 151-7. 10.1007/s10096-003-0902-x

51. Davies MS, Robertson MB, Brown SHA, et al. Variability of antimicrobial prescribing in patients with acute cellulitis. *Eur J Clin Pharmacol* 2012; **68**(9): 1303-7. 10.1007/s00228-012-1240-7.

52. Figtree M, Konecny P, Jennings Z, et al. Risk stratification and outcome of cellulitis admitted to hospital. *J Infect* 2010; **60**(6): 431-9. 10.1016/j.jinf.2010.03.014

53. Jenkins TC, Sabel AL, Sarcone EE, et al. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. *Clin Infect Dis* 2010; **51**(8): 895-903. 10.1086/656431

54. Lazzarini L, Conti E, Tositti G, et al. Erysipelas and cellulitis: Clinical and microbiological spectrum in an Italian tertiary care hospital. *J Infect* 2005; **51**(5): 383-9. 10.1016/j.jinf.2004.12.010

55. Lee CY, Tsai HC, Kunin CM, et al. Clinical and microbiological characteristics of purulent and non-purulent cellulitis in hospitalized Taiwanese adults in the era of community-associated methicillin-resistant Staphylococcus aureus. *BMC Infect Dis* 2015; **15**(311). 10.1186/s12879-015-1064-z.

56.   Solomon M, Barzilai A, Elphasy H, et al. Corticosteroid therapy in combination with antibiotics for erysipelas. *Isr Med Assoc J* 2018; **20**(3): 137-40.

57.   Vanlangen KM, Dumkow LE, Axford KL, et al. Evaluation of a multifaceted approach to antimicrobial stewardship education methods for medical residents. *Infect Control Hosp Epidemiol* 2019; **40**(11): 1236-41. http://dx.doi.org/10.1017/ice.2019.253

58.   Moore SJ, O'Leary ST, Caldwell B, et al. Clinical characteristics and antibiotic utilization in pediatric patients hospitalized with acute bacterial skin and skin structure infection. *Pediatr Infect Dis J* 2014; **33**(8): 825-8. 10.1097/INF.0000000000000304.

59.   Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. *Med J Aust* 1998; **169**(10): 519-22.

60.   Ong BS, Ngian VJJ, Yeong C, et al. Out Of Hospital And In Hospital Management Of Cellulitis Requiring Intravenous Therapy. *Int J Gen Med* 2019; **12**: 447-53. 10.2147/IJGM.S230054

61.   Bader MS, Twells L, Hawboldt J. Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid. *South Med J* 2011; **104**(12): 789-93. 10.1097/SMJ.0b013e3182387365.

62.   Chan M, Ooi CK, Wong J, et al. Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore. *BMC Infect Dis* 2017; **17**: 474. 10.1186/s12879-017-2569-4.

63.   Donald M, Marlow N, Swinburn E, et al. Emergency department management of home intravenous antibiotic therapy for cellulitis. *Emergency medicine* 2005; **22**(10): 715-7. 10.1136/emj.2004.018143

64.   Hurley HJ, Knepper BC, Price CS, et al. Avoidable antibiotic exposure for uncomplicated skin and soft tissue infections in the ambulatory care setting. *Am J Med* 2013; **126**(12): 1099-106. 10.1016/j.amjmed.2013.08.016.

65.   Landry D, Eltonsy S, Jalbert LP, et al. Continuous cefazolin infusion versus cefazolin plus probenecid for the ambulatory treatment of uncomplicated cellulitis: A retrospective cohort study. *Pharmacoepidemiol Drug Saf* 2019; **28**(Supplement 2): 129. http://dx.doi.org/10.1002/pds.4864

66.   Lillie PJ, Andrews D, Eaves K, et al. Baseline factors predicting the duration of intravenous antibiotic therapy for cellulitis in an outpatient setting. *Eur J Clin Microbiol Infect Dis* 2010; **29**(3): 347-9. 10.1007/s10096-009-0855-9

67.   Rentala M, Andrews S, Tiberio A, et al. Intravenous Home Infusion Therapy Instituted from a 24-Hour Clinical Decision Unit for Patients with Cellulitis. *Am J Emerg Med* 2016; **34**(7): 1273-5. 10.1016/j.ajem.2016.04.022.

68.   Ibrahim LF, Hopper SM, Babl FE, et al. Who can have parenteral antibiotics at home? A prospective observational study in children with moderate/severe cellulitis. *Pediatr Infect Dis J* 2016; **35**(3): 269-74. 10.1097/INF.0000000000000992.

69.   Zhang J, Moore E, Bousfield R. OPAT for cellulitis: its benefits and the factors that predispose to longer treatment. *Eur J Clin Microbiol Infect Dis* 2016; **35**(6): 1013-5. 10.1007/s10096-016-2631-y

70.   Smith E, Patel M, Thomas KS. Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey. *Br J Dermatol* 2018; **178**(5): 1028-34. 10.1111/bjd.16235

71.   Hirschmann JV, Raugi GJ. Lower limb cellulitis and its mimics: part I. Lower limb cellulitis. *J Am Acad Dermatol* 2012; **67**(2): 163 e1-12; quiz 75-6. 10.1016/j.jaad.2012.03.024

72.   Levell NJ, Wingfield CG, Garioch JJ. Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. *Br J Dermatol* 2011; **164**(6): 1326-8. 10.1111/j.1365-2133.2011.10275.x

73.   Weng QY, Raff AB, Cohen JM, et al. Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis. *JAMA Dermatol* 2017; **153**(2): 141-6. 10.1001/jamadermatol.2016.3816

74.   Schweitzer VA, van Heijl I, van Werkhoven CH, et al. The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. *Clin Microbiol Infect* 2019; **25**(5): 555-61. 10.1016/j.cmi.2018.11.002

75.   Seide SE, Rover C, Friede T. Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies. *BMC Med Res Methodol* 2019; **19**(1): 16. 10.1186/s12874-018-0618-3

76.   Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. *Int J Epidemiol* 2007; **36**(3): 666-76. 10.1093/ije/dym018

77.   Snodgrass WR, Anderson T. Prontosil in Erysipelas: a controlled series of 312 cases. *Bmj* 1937; **2**(3993): 101-4. 10.1136/bmj.2.3993.101

78.   Snodgrass WR, Anderson T. Sulphanilamide in the Treatment of Erysipelas. *Br Med J* 1937; **2**(4014): 1156-9. 10.1136/bmj.2.4014.1156

Figure 1. Study selection

```
┌─────────────────────────┐   ┌─────────────────────────┐
│ 10,170 records identified│   │ 1131 records identified │
│ through database searching│  │ through other sources   │
└───────────┬─────────────┘   └───────────┬─────────────┘
            │                             │
            └──────────────┬──────────────┘
                           ▼
            ┌─────────────────────────┐
            │ 8423 records after       │
            │ duplicates removed       │
            └───────────┬─────────────┘
                        │
                        ▼
            ┌─────────────────────────┐        ┌─────────────────────────┐
            │ 8423 abstracts screened  │───────▶│ 7819 articles excluded  │
            └───────────┬─────────────┘        └─────────────────────────┘
                        │
                        ▼
            ┌─────────────────────────┐        ┌──────────────────────────────────────┐
            │ 604 full-text articles   │───────▶│ 557 full-text articles excluded,     │
            │ assessed for eligibility │        │ with reasons                         │
            └───────────┬─────────────┘        │                                      │
                        │                       │   342 did not report separate data   │
                        ▼                       │   for cellulitis population          │
            ┌─────────────────────────┐        │   82 had no appropriate comparison‡  │
            │ 47* articles included    │        │   73 did not report average duration │
            │ in narrative synthesis   │        │   of antibiotic therapy              │
            │                          │        │   31 ineligible study design         │
            │ *48 studies              │        │   18 not in English                  │
            └───────────┬─────────────┘        │   7 did not report relevant outcomes │
                        │                       │   4 studied inappropriate antibiotic │
                        ▼                       │   route                              │
            ┌─────────────────────────┐        │                                      │
            │ 10†articles included in  │        │ ‡ for example, compared different    │
            │ meta-analyses            │        │ antibiotic agents without comparing  │
            │                          │        │ IV to oral therapy or shorter to     │
            │ †11 studies              │        │ longer duration of therapy           │
            └─────────────────────────┘        └──────────────────────────────────────┘
```

**Figure 2. Summary of risk of bias across RCTs.**

Table 1. Characteristics of studies comparing oral versus IV with step down to oral treatment

Author & year	Study design	Setting	Population	Severity & site	Oral antibiotic arm	IV antibiotic arm	Primary outcome	Findings	
								Oral arm	IV arm
Aboltins 2015	RCT	Single tertiary teaching hospital, Australia Inpatients & OPAT	47 adults with cellulitis	Uncomplicated (not mild) - 87% lower limb - 13% upper limb	Oral cephalexin* 10 days	IV-to-oral cefazolin to cephalexin * 10 days	Mean days until no advancement of the area of cellulitis	1.29 (SD 0.62) days (n=24)	1.78 (SD 1.13) days (n=23)
								Mean difference -0.49 (95% CI, -1.02 to +0.04)	
Bernard 1992	RCT	6 dermatological departments, France Inpatients	69 adults with erysipelas	Non-gangrenous erysipelas - Site NR	Oral roxithromycin Average duration (range) 13 days (2 to 29)	IV-to-oral penicillin Average IV duration (range) 6 days (2 to 17) Average oral duration 7 days (0 to 21)	Efficacy rate Timing NR (some point within 30 days)	26/31 (84%)	29/38 (76%) (P=0.43)
Bernard 2002	RCT	22 dermatology centres, France Inpatients	289 adults with erysipelas	Superficial, non-necrotising - 94% lower limb	Oral pristinamycin 14 days	IV-to-oral benzylpenicillin to phenoxymethylpenicillin 14 days	Clinical cure rate Day 25 to 45	90/138 (65%)†	79/150 (53%)†
Thomas 2014	RCT	Single hospital, New Zealand Inpatients	40 adults with cellulitis	Severity NR - 78% lower limb - 10% upper limb	Oral clindamycin Median no. of doses of IV 'treatment'‡ (range) 11 (0 to 15)	IV-to-oral flucloxacillin Median no. of doses of IV treatment (range) 8 (0 to 21), (P=0.23)	Clinical efficacy Daily review at 'completion of treatment'	21/21 (100%) Cured 18/21 (86%) Improved 3/21 (14%)	18/19 (95%) Cured 7/19 (37%) Improved 11/19 (58%)
					Median oral duration (range) 9 days (0 to 21)	Median oral duration 8 (0 to 18), (P=0.81)			
Jorup-Rönström 1984	Quasi-RCT	Single hospital, Sweden Inpatients	73 adults with erysipelas	'severe local findings' - Site NR	Oral phenoxymethylpenicillin ± flucloxacillin For at least 10 days	IV-to-oral Benzylpenicillin ± cloxacillin For at least 10 days	Time to temperature fall to ≤37.5°C (median fever duration)	2 days	3 days

NR = Not reported. Primary outcome defined by study authors, where not defined the first outcome measure of clinical response to be reported was selected. *Clindamycin if penicillin allergic. †In the intention-to-treat (ITT) analysis. ‡Placebo IV treatment given in the oral clindamycin arm.

Figure 3. Forest plot of comparison: Oral versus IV antibiotics, outcome clinical response

	Oral		IV			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M–H, Random, 95% CI
Bernard 1992	26	31	29	38	23.2%	1.10 [0.87, 1.39]
Bernard 2002	90	138	79	150	30.7%	1.24 [1.02, 1.50]
Thomas 2014	21	21	18	19	46.1%	1.06 [0.92, 1.22]
Total (95% CI)		190		207	100.0%	1.12 [0.98, 1.27]
Total events	137		126			

Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 2.95$, $df = 2$ (P = 0.23); $I^2 = 32\%$

Test for overall effect: Z = 1.71 (P = 0.09)

Risk Ratio
M–H, Random, 95% CI

0.5   0.7   1   1.5   2
Favours IV   Favours oral

Table 2. Summary of studies reporting on timing of IV-to-oral switch

Study	Design	Setting	Population	Relevant Outcome	Finding
Clarke 2019 Switch Trial	RCT comparing early (24h) vs later (≥72h) oral switch	10 sites, Australia & New Zealand Inpatients & OPAT	80 adults with cellulitis requiring IV therapy (39 in shorter, 41 in longer group)	Resolution of cellulitis at the end of therapy (10 days after randomisation)	Cellulitis resolution achieved in 31 (79%) in shorter group and 35 (85%) in longer group (difference of -5.8% (95%CI, -22.5% to 10.7%)
Bogner 2013	Prospective, multicentre cohort study describing outcomes among patients treated with moxifloxacin	>600 sites, Europe, the Middle East and Asia-Pacific region Inpatients	5444 adults and children with complicated SSTIs, 820 with cellulitis	Effectiveness (improvement and resolution of cellulitis) at follow-up	Mean IV-to-oral switch time of 3.4 days associated with 'very good' (68%), 'good' (26%) and 'sufficient' (3%) effectiveness ratings
Lipsky 2012	Prospective, multicentre cohort study describing patient characteristics and treatment outcomes in cellulitis	56 hospitals, USA Inpatients	1033 adults with complicated SSTIs, 278 with cellulitis	Clinical response at the end of IV treatment	Mean IV duration of 2 to 3 days associated with cure in 11.9% and improvement in 78.4%
Morpeth 2005	Prospective cohort study assessing determinants of LOS, length of IV antibiotic therapy and outcomes in cellulitis	Single hospital, New Zealand Inpatients	51 adults with cellulitis	Recurrence of cellulitis within six weeks of discharge	Median IV duration of 3 days, 12% were readmitted to hospital for recurrence
McNamara 2007	Retrospective cohort to examine risk factors and develop a predictive model for recurrent lower limb cellulitis	Multicentre, USA Inpatients and outpatients	209 adults with cellulitis	Recurrence of cellulitis within 2 years	Mean IV duration of 1.1 days, 35 (16.7%) experienced a recurrence within 2 years
Gouin 2008	Prospective cohort study assessing outcomes of children with cellulitis managed at a day treatment centre	Single hospital, Canada OPAT/day treatment centre	92 children with cellulitis	Relapse of cellulitis within 14 days	Mean IV duration of 2.5 days at which point 19 children received further 4.5 days IV therapy and 73 were discharged on oral therapy. 1/73 relapsed
Ibrahim 2017	Prospective cohort study describing outcomes of children with cellulitis treated on an admission avoidance pathway	Single hospital, Australia OPAT & inpatients	115 children with cellulitis (47 OPAT, 68 inpatients)	Treatment failure within 48 hours	Median duration of IV therapy similar between OPAT and inpatient groups (1.9 vs. 1.8 days, P=0.31) as was treatment failure (4% vs. 14%, P=0.10)

Table 3. Characteristics of RCTs comparing shorter versus longer duration antibiotics

Author & year	Setting	Population	Severity & site	Shorter arm	Longer arm	Primary outcome	Findings Shorter arm	Findings Longer arm
Daniel 1991 part 1	29 centres, 6 European countries In-/outpatient, unclear	122 adults with cellulitis (308 SSTIs)	Severity & site NR	5 days of oral azithromycin	7 days of oral erythromycin	Clinical cure 7-10 days after treatment completion	52/72 (72%)	37/50 (74%)
Daniel 1991 part 2	15 centres, 4 European countries In-/outpatient, unclear	62 adults with cellulitis (323 SSTIs)	Severity & site NR	5 days of oral azithromycin	7 days of oral cloxacillin	Clinical response 4-9 days post treatment completion	41/41 (100%) Cured 27/41 (66%) Improved 14/41 (34%)	21/21 (100%) Cured 11/21 (52%) Improved 10/ 21 (48%)
Kiani 1991	22 centres, USA Inpatients & outpatients	47 adults with cellulitis (366 SSTIs)	Severity & site NR	5 days oral azithromycin	10 days of oral cephalexin	Clinical response Day 11 (10-13)	23/24 (96%) Cured 12/24 (50.0%) Improved 11/24 (45.8%)	22/23 (96%) Cured 14/23 (60.9%) Improved 8/23 (34.8%)
Hepburn 2004	Single tertiary care military hospital, USA Inpatients & outpatients	87 adults with cellulitis	Uncomplicated Face, trunk or extremity	5 days of levofloxacin*	10 days of levofloxacin*	Resolution of infection Day 14 (without symptom recurrence by day 28)	43/44 (98%)	42/43 (98%)
Prokocimer 2013 *(ESTABLISH 1)*	81 centres, North America, Latin America and Europe In-/outpatient, unclear	275 adults with cellulitis (667 SSTIs)	Complicated Site NR	6 days oral tedizolid	10 days oral linezolid	Early clinical response 48-72hrs after the start of treatment	101/135 (74.8%)	100/139 (71.9%)
Moran 2014 *(ESTABLISH 2)*	58 centres, various countries† In-/outpatient, unclear	334 adults & children (age range 15-89) with cellulitis (666 SSTIs)	Complicated Site NR	6 days IV-to-oral tedizolid	10 days IV-to-oral linezolid	Early clinical response 48-72hrs after the start of treatment	134/166 (81%) Treatment difference 0.3% (95% CI, -8.2 to 8.9%)	135/168 (80%)
Lv 2019	Multicentre, USA, China, Taiwan and the Philippines In-/outpatient, unclear	383 adults with cellulitis (598 SSTIs)	Complicated - 59% lower limb - 12% upper limb	6 days IV-to-oral tedizolid	10 days IV-to-oral oral linezolid	Early clinical response 48-72hrs after the start of treatment	135/192 (70.3%)	150/191 (78.0%)
Cranendonk 2019	11 centres, the Netherlands Inpatients	149 adults with cellulitis	'High severity' - 84% lower limb - 9% upper limb	6 days IV-to-oral flucloxacillin	12 days IV-to-oral flucloxacillin	Cure by day 14 without relapse by day 28	36/73 (49%)	38/76 (50%)
Paediatric studies								
Rodriguez-Solares 1993	5 centres, Costa Rica, Guatemala, Panama, Venezuela Outpatients	16 children with cellulitis (118 with SSTIs)	Severity & site NR	Oral azithromycin for 3 days	Oral dicloxacillin or flucloxacillin for 7 days	Clinical response 7-10 days after the start of treatment	5/5 (100%) Cured 4/5 (80%) Improved 1/5 (20%)	11/11/ (100%) Cured 11/11 (100%) Improved 0/11 (0%)

| Montero 1996 | 'Multicentre', Colombia, Guatemala, Panama, South Africa Inpatients | 34 children with cellulitis (200 SSTIs) | Severity & site NR | Oral azithromycin for 3 days | Oral cefaclor for 10 days | Clinical efficacy (cured/improved) 10-14 days after the start of treatment | 13/16 (81%) | 16/18 (89%) |

NR = Not reported. Primary outcome defined by study authors, where not defined the first outcome measure of clinical response to be reported was selected. *Mostly oral (12 IV-to-oral). [†]Argentina, Australia, Germany, New Zealand, Poland, Russia, South Africa, Spain, and the USA.

**Figure 4. Forest plot of comparison: Shorter versus longer duration antibiotics, outcome clinical response**

Study or Subgroup	Shorter duration Events	Total	Longer duration Events	Total	Weight	Risk Ratio M–H, Random, 95% CI
1.1.1 Same antibiotics						
Cranendonk 2019	36	73	38	76	1.3%	0.99 [0.71, 1.36]
Hepburn 2004	43	44	42	43	32.3%	1.00 [0.94, 1.07]
Subtotal (95% CI)		117		119	33.6%	1.00 [0.94, 1.07]
Total events	79		80			

Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)

Study or Subgroup	Shorter duration Events	Total	Longer duration Events	Total	Weight	Risk Ratio M–H, Random, 95% CI
1.1.2 Different antibiotics in same class						
Daniel 1991 part 1	52	72	37	50	2.8%	0.98 [0.78, 1.21]
Lv 2019	135	192	150	191	9.6%	0.90 [0.80, 1.01]
Moran 2014	134	166	135	168	12.1%	1.00 [0.90, 1.12]
Prokocimer 2013	101	135	100	139	6.6%	1.04 [0.90, 1.20]
Subtotal (95% CI)		565		548	31.1%	0.97 [0.91, 1.04]
Total events	422		422			

Heterogeneity: Tau² = 0.00; Chi² = 3.10, df = 3 (P = 0.38); I² = 3%
Test for overall effect: Z = 0.77 (P = 0.44)

Study or Subgroup	Shorter duration Events	Total	Longer duration Events	Total	Weight	Risk Ratio M–H, Random, 95% CI
1.1.3 Different antibiotics in different class						
Daniel 1991 part 2	41	41	21	21	26.0%	1.00 [0.93, 1.07]
Kiani 1991	23	24	22	23	9.2%	1.00 [0.89, 1.13]
Subtotal (95% CI)		65		44	35.3%	1.00 [0.94, 1.06]
Total events	64		43			

Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.02 (P = 0.99)

Study or Subgroup	Shorter duration Events	Total	Longer duration Events	Total	Weight	Risk Ratio M–H, Random, 95% CI
Total (95% CI)		747		711	100.0%	0.99 [0.96, 1.03]
Total events	565		545			

Heterogeneity: Tau² = 0.00; Chi² = 4.18, df = 7 (P = 0.76); I² = 0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi² = 0.42, df = 2 (P = 0.81), I² = 0%

Favours longer duration   Favours shorter duration

Table 4. Summary of non-randomised studies reporting on shorter versus longer duration antibiotics

Study	Design	Setting	Population	Relevant Outcome	Finding
Jenkins 2011	Retrospective pre- and post-intervention study evaluating a guideline for the inpatient management of cellulitis	Single hospital, USA Inpatients	148 adults with cellulitis (66 pre-, 82 post-intervention)	Composite endpoint of clinical failure within 30 days of discharge	From pre-to post-intervention, median antibiotic duration decreased from 13 to 10 days (P<0.001) and clinical failure rates remained similar 12.1% vs. 9.8% (P=0.65), respectively
Seaton 2005	Pre- and post-intervention study evaluating a new protocol for specialist nurse management of cellulitis through an OPAT service	Single centre, Glasgow OPAT	342 adults & children with cellulitis	Clinical response (cure/improved) at 'completion of treatment'	From pre-to post-intervention, median antibiotic duration decreased from 5 to 4 days (P=0.01) and clinical response rates remained similar 99% vs. 97%, respectively
Aly 1996	Retrospective observational study examining the management of cellulitis in a teaching hospital	Tertiary teaching hospital, Australia Inpatients	118 adults with cellulitis	Clinical response (not clearly defined) within 5 days	Most patients (93%) had a clinical response within 5 days. However, 40% of the cohort continued IV therapy for >5 days and in 10% for >10 days, with no evidence of difference in outcomes
Kam 2010	Retrospective observational study comparing emergency department short-course IV therapy vs. inpatient IV therapy or outpatient oral antibiotics	Single hospital, Canada Inpatients and outpatients	321 children with cellulitis	Treatment failure within 7 days of index visit	The odds of treatment failure were higher for short-course IV therapy compared to inpatient IV therapy (7.2, 95% CI 1.6 to 33.1) and outpatient oral antibiotics (3.2, 95% CI 1.3 to 8.3)